Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
Smati, Sarra, Sotin, Thibaud, Deniel, Perrine, Ducheix, Simon, Joubert, Michael, Arnaud, Lucie, Hadjadj, Samy, Cariou, Bertrand, Le May, Cédric, Prieur, Xavier
Published in Diabetes, obesity & metabolism (01.08.2024)
Published in Diabetes, obesity & metabolism (01.08.2024)
Get full text
Journal Article